- Home
- CRBU vs JRS Comparison
CRBU vs JRS Comparison
Compare CRBU & JRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBU
- JRS
- Stock Information
- Founded
- CRBU 2011
- JRS 2001
- Country
- CRBU United States
- JRS United States
- Employees
- CRBU N/A
- JRS N/A
- Industry
- CRBU Medicinal Chemicals and Botanical Products
- JRS Finance/Investors Services
- Sector
- CRBU Health Care
- JRS Finance
- Exchange
- CRBU Nasdaq
- JRS Nasdaq
- Market Cap
- CRBU 236.3M
- JRS 267.5M
- IPO Year
- CRBU 2021
- JRS N/A
- Fundamental
- Price
- CRBU $1.79
- JRS $8.32
- Analyst Decision
- CRBU Strong Buy
- JRS
- Analyst Count
- CRBU 4
- JRS 0
- Target Price
- CRBU $12.00
- JRS N/A
- AVG Volume (30 Days)
- CRBU 1.5M
- JRS 86.6K
- Earning Date
- CRBU 11-06-2024
- JRS 01-01-0001
- Dividend Yield
- CRBU N/A
- JRS 8.87%
- EPS Growth
- CRBU N/A
- JRS N/A
- EPS
- CRBU N/A
- JRS N/A
- Revenue
- CRBU $11,475,000.00
- JRS N/A
- Revenue This Year
- CRBU N/A
- JRS N/A
- Revenue Next Year
- CRBU N/A
- JRS N/A
- P/E Ratio
- CRBU N/A
- JRS N/A
- Revenue Growth
- CRBU N/A
- JRS N/A
- 52 Week Low
- CRBU $1.50
- JRS $5.95
- 52 Week High
- CRBU $8.33
- JRS $8.00
- Technical
- Relative Strength Index (RSI)
- CRBU 37.96
- JRS 23.00
- Support Level
- CRBU $1.72
- JRS $8.09
- Resistance Level
- CRBU $1.97
- JRS $9.48
- Average True Range (ATR)
- CRBU 0.14
- JRS 0.17
- MACD
- CRBU -0.03
- JRS -0.15
- Stochastic Oscillator
- CRBU 9.12
- JRS 7.75
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies.
About JRS Nuveen Real Estate Income Fund of Beneficial Interest
Nuveen Real Estate Income Fund is a diversified closed-end investment company. The Fund invests primarily in income-producing common stocks, preferred stocks, convertible preferred stocks, and debt securities issued by real estate companies. At least 75% of the Fund's managed assets will be in securities rated investment grade.